Home › All Companies › STOK › Insider Trading

Stoke Therapeutics, Inc. (STOK) — Insider Trading

AI-Powered SEC Filing Analysis

← All STOK filings
Latest Insider Trading Filed: 2026-04-07

Key Insights

  • Director Clare Kahn acquired 30,782 stock options with an exercise price of $32.79, which will vest over 4 years. This represents a significant long-term commitment from an insider.
  • The large option grant suggests Kahn has a positive outlook on Stoke Therapeutics' future and is willing to tie her compensation to the company's stock performance.
  • Insider buying can signal management's confidence in the company's prospects, which may be of interest to investors evaluating Stoke Therapeutics.
Sentiment: Positive Significance: 7/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-04-07. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Stoke Therapeutics, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.